Tuesday, 21 July 2020

India CRO Market Forecasts By Industry Drivers, Regions Till 2023

Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period with overview of top cro companies in India.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
The market constraints that can hamper the growth of India CRO market include growing concern for security especially data security and patient security and lack of collaboration between universities and industry etc. Sometimes, some unethical Indian CROs make dishonest comprises which creates trust issues among potential clients for CROs and hurts the market.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The western and southern regions of India hold a strong position in the CRO market due to their better infrastructure, education and salubrious climate. However the northern regions have started growing and catching up due to larger and more diverse genetic pool and the concentration of regulatory bodies in northern India. The faster growth of hospitals in northern India is favoring the CRO market and has led to this shift. The growth of diseases needing specialized care and treatments such as cancer is booming the CRO market of this segment at a faster pace than other segments.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.

Carcinoid Syndrome Management Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2022

Market Scenario:
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome diagnosis market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.

Osteoporosis Drugs Market Professional Overview 2019-2022 With Major Vendors Size, Shares And Worldwide Demand

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Global Osteoporosis Drugs Market Report - Forecast to 2022” Gives industry size, top players and worldwide demand
Market Synopsis of Global Osteoporosis Drugs Market:
Market Scenario:
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.
Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.

Study Objectives Global Osteoporosis Drugs Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Key Players for Global Osteoporosis Drugs Market:

Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Intended Audience:
  • Osteoporosis Drugs Manufacturers
  • Osteoporosis Drugs Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations
Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Anti-viral drugs Market 2022 – Market Size, Share, Trends Analysis And Growth Forecast

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Key Players
MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 

The Bioinformatics Market World Leading Key Players Revenue, Share, Analysis And Estimation Till 2022

Bioinformatics Market Overview
According to Market Research Future (MRFR), the global bioinformatics market is projected to register CAGR of 19.8% from 2016 to 2022 (forecast period).
Bioinformatics is a combination of biology and information technology that combines biological data with information storage, distribution, and analysis techniques to support multiple areas of scientific research, including biomedicine. It uses software tools for data storage, database creation, data management, data mining, etc. The mining of these data contributes to scientific findings that are used in the study of genetics and genomes. Several bioinformatics tools are available on the market. They are categorized as functional protein & analysis tools, homology & similarity tools, sequence analysis tools, and various tools. The field encompasses a number of advanced and specialized areas of life, such as structural genomics, DNA microarrays, functional genomics, comparative genomics, medical information, and others. Such factors, therefore, help to increase the global market share of bioinformatics. 
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/2265
Bioinformatics Market Dynamics
The growth of bioinformatics is accelerated by the growing use of information technology in the healthcare sector, along with robust technological advances. The use of information technology has made it easier to store, process, access, and retrieve data. In addition, the need for innovative treatment for many diseases and successful preventive approaches continues to increase. With an increasing demand for innovation in technologies used to treat a variety of diseases, many healthcare practitioners tend to concentrate on research and development projects. In addition, the rise in R&D activities has led to an increase in the generation of data, increasing the need for effective data management technology in the healthcare sector.
However, the lack of qualified personnel, common data formats, and lack of user-friendly tools at lower prices are estimated to hinder the market growth during the forecast period. 
Bioinformatics Market Segmentation   
The global bioinformatics market has been segmented into application, services and technology, and sector. 
Based on the application, the global market for bioinformatics has been segmented into genomics, chemo-informatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences, and others. Genomics was the leading technology in 2013. Growing demand for pharmacogenomics in the drug development and sequence screening and implementation of technical developments aimed at handling vast sets of genomic data are key factors that account for the market share. Chemo-informatics is projected to rise steadily over the forecast period. Growing demand for biomarker discovery and production is the primary reason for projected growth over the forecast period. The transcriptomics segment is estimated to have the highest growth during the forecast period due to increased preference for companion diagnostics and personalized medicines.
Based on services and technology, the global market for bioinformatics has been segmented into data warehousing, sequence analysis, sequence manipulation, and others. 
Based on sector, the global market for bioinformatics has been segmented into medical bioinformatics, animal bioinformatics, agriculture bioinformatics, and others. 
Bioinformatics Market Regional Analysis
The global bioinformatics market has been segmented into the Americas, Asia Pacific, Europe, and the rest of the world.
The Americas is the largest bioinformatics market in the world. Heavy investment in research and development, high adoption of new and advanced technology, well-structured regulatory outlines, and the prevalence of advanced technology are factors driving market growth in the regions.
Europe is projected to be the second-largest market over the forecast period. 
The Asian Pacific market is anticipated to be the fastest-growing market for bioinformatics. 
Bioinformatics Market Key Players                                                     
Some of the significant participants in the global bioinformatics market are Agilent Technologies, QIAGEN N. V, and Thermo Fisher Scientific Inc., Illumina, Inc., Dassault Systèmes, QIAGEN, and others.   
Table of Content
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL BIOINFORMATICS MARKET, BY APPLICATION
...TOC Continued
List Of Tables
TABLE 1 GLOBAL BIOINFORMATICS MARKET, BY APPLICATION, 2013-2022 (USD MILLION)
TABLE 2 GLOBAL BIOINFORMATICS MARKET, BY TECHNOLOGY AND SERVICES, 2013-2022 (USD MILLION)
TABLE 3 GLOBAL BIOINFORMATICS MARKET, BY SECTOR, 2013-2022 (USD MILLION)
TABLE 4 GLOBAL BIOINFORMATICS MARKET, BY REGION, 2013-2022 (USD MILLION)
List Of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL BIOINFORMATICS MARKET, BY APPLICATION
FIGURE 4 GLOBAL BIOINFORMATICS MARKET, BY TECHNOLOGY AND SERVICES
FIGURE 5 GLOBAL BIOINFORMATICS MARKET, BY SECTOR
FIGURE 6 GLOBAL BIOINFORMATICS MARKET, BY REGION
FIGURE 7 GLOBAL BIOINFORMATICS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)
...
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/bioinformatics-market-2265 

Global Neurostimulation Devices Market Expected Tremendous Growth Till 2022

Market Scenario:
Neurostimulation is a modulation of the nervous system’s activity. It is deliberately carried out by using invasive and non-invasive techniques. Implantable stimulation devices are most commonly used in the treatment of the neurological conditions such as epilepsy, Parkinson’s disease, dystonia, tremors, depression, obsessive compulsive disorder, diabetic neuropathy and few other conditions. Increasing cases of the neurological disorders such as chronic pain and depression high adoption of the Neurostimulation therapy are likely to improve the market of Neurostimulation devices. Globally, this Neurostimulation Devices Market Size is growing steadily and it is anticipated to show an exponential growth reaching approximately $11.5 billion in 2022
Segments:
Global Neurostimulation devices market has been segmented on the basis of type which comprises implantable devices, and external devices. Implantable devices include deep brain stimulators, spinal cord stimulators, sacral nerve stimulators, gastric electric stimulators, cochlear implants, and vagus nerve stimulators; whereas external devices include transcutaneous electrical nerve stimulator, and transcranial magnetic stimulator. On the basis of application, the market is segmented into dystonia, epilepsy, Parkinson's disease, depression, gastroparesis, pain management, tremors, urinary and fecal incontinence, and others. On the basis of end user, market is segmented into hospitals/clinics, cognitive care centers, research institutes and others.
Regional Analysis of Neurostimulation devices Market:
Considering the global scenario of the market, Americas region is believed to be the largest market for Neurostimulation devices. Moreover, the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Neurostimulation devices segment during the forecast period. Middle East & Africa region are likely to have a limited but steady growth in the market.
Key Players for Neurostimulation devices Market:                                     
Some of the key players in this market are: Autonomic Technologies, Boston Scientific, ElectroCore, ImThera Medical, Inspire Medical Systems, LivaNova (Cyberonics), Medtronic, NeuroMetrix, NeuroPace, Neuros Medical, NeuroSigma, Nevro Corporation, SPR Therapeutics, St.Jude Medical, Synapse Biomedical, and others.   
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global Neurostimulation Devices market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the Neurostimulation Devices market in this region.
Europe is expected to hold the second largest market share in the global Neurostimulation Devices market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the Neurostimulation Devices market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the Neurostimulation Devices market during the forecast period.

Regenerative Medicine Market Leading Regenerative Medicine Market Key Developments Trends, Analysis And Forecasts Till 2022

Market Scenario:
The Global Regenerative Medicine Market trends are growing steadily. Factors that influence the regenerative medicine market are increasing advancement in healthcare technology, increasing advance technology in regenerative medicine market, increasing prevalence of chronic diseases, increasing growth in stem cell technology and others. Globally  regenerative medicine market size is expected to grow at the rate of about 25.4% from 2016 to 2022.
Investments are likely to flow towards the regenerative medicine industry over the next couple of years. In addition, the support extended by the government for drug development is poised to revolutionize the future trajectory of the global market. It is also likely to benefit from technological advancements in the market.
Stem cell technology is gaining traction in the healthcare sector. Its accelerated adoption in the field of medical science is also anticipated to have a favorable impact on the expansion of the regenerative medicine market. The players of the market are forecasted to capitalize on the gap prevailing between the demand and supply for organs. However, factors such as stringent regulations, and the high cost of the treatment are expected to check the proliferation of the regenerative medicine market through the projection period.
Market Segmentation:
on the basis of material, the regenerative medicine market has been segmented into synthetic materials, genetically engineered materials, pharmaceuticals, biologically derived materials, and others.
On the basis of therapy, the global regenerative medicine market has been segmented into stem cell biology, cellular therapy, tissue engineering, and others.
On the basis of application, the regenerative medicine market has been segmented into cord blood, oncology, urology, orthopedics, neurology, dermatology, cardiovascular, orthopedic and others.
Competitive Dashboard:
Some of the key players profiled in the report are Cook Biotech, Organogenesis, Stryker and RTI surgical, Baxter International, Inc., Osiris Therapeutics, CryoLife, Sanofi, LifeSciences, Advanced Cell Technology, BioMimetic Therapeutics, LifeCell Kinetic Concepts, StemCellsInc, and Medtronic.
Regional Analysis:
The global regenerative medicine market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is currently holding the largest share of the market, accounting for 44% share. It is expected to grow significantly at a CAGR of 22.3% during the forecast period. The factors such as developments in healthcare technology, presence of advanced healthcare infrastructure, increasing burden of chronic diseases, etc.
Europe has gained control over the second-largest share of the market. It is expected to strike a high CAGR of 22.5% over the assessment period. The availability of funds coupled with the government’s support is likely to accelerate research & development activities. This, in turn, is prognosticated to boost the growth trajectory of the regional regenerative medicine market in the upcoming years.
Asia Pacific is a highly lucrative market and is expected to remain so across the review period. The rapid developments in the healthcare sector and growing patient pool are anticipated to drive the expansion of the regenerative medicine market in the region. It is estimated to mark a relatively higher CAGR and emerge as the fastest growing regional market in the foreseeable future.
Industry News:
In November 2018, 3D.FAB, a French additive manufacturing platform, has announced that it is working on the development of a “living bandage” using direct additive manufacturing and 3D bioprinting for treating damaged tissues.
In December 2018, Food and Drug Administration has sent Genetech, a CA-based biotechnology subsidiary of Roche, and other firms and providers offering stem cell treatments warning letters to notify about agency's regenerative medicine policy framework.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com